Brolucizumab preserves vision, raises inflammation
- JAMA Ophthalmology published the phase 3 CONDOR trial on April 23, finding brolucizumab matched laser on vision and reduced active diabetic retinopathy at 54 weeks. - The randomized study enrolled 689 patients across 16 countries; brolucizumab was dosed every 6 weeks, then every 12 weeks, with extension to 24 weeks. - The tradeoff is safety and follow-up burden: injections outperformed laser on disease control but carried inflammation risk. (jamanetwork.com)
Proliferative diabetic retinopathy is the advanced stage of diabetes-related eye disease, when the retina grows fragile new blood vessels that can bleed and scar. JAMA Ophthalmology reported April 23 that brolucizumab injections matched panretinal photocoagulation laser on vision and left fewer eyes with active disease at 54 weeks. (jamanetwork.com) Panretinal photocoagulation, or PRP, treats the problem by using laser burns to lower the retina’s oxygen demand. Anti-vascular endothelial growth factor drugs such as brolucizumab work differently: they block the growth signal that drives those abnormal vessels. (jamanetwork.com) The phase 3 CONDOR trial randomized 689 participants in 16 countries at 152 sites to either brolucizumab 6 milligrams or PRP. Patients in the injection arm got three loading doses every six weeks, then maintenance every 12 weeks, with later extension up to 24 weeks if disease stayed quiet. (jamanetwork.com) (clinicaltrials.gov) The trial’s main test was best-corrected visual acuity at week 54, and brolucizumab met the study goal of noninferiority versus laser. The paper’s key-point summary also said eyes in the brolucizumab group were less likely to still have proliferative diabetic retinopathy at week 54. (jamanetwork.com) (pubmed.ncbi.nlm.nih.gov) That result lands in a treatment debate that has been shifting for years. A 2024 JAMA Ophthalmology cohort study found eyes treated with anti-vascular endothelial growth factor first, then PRP, had lower risks of vitreous hemorrhage, tractional retinal detachment, and vitrectomy than eyes treated with PRP first. (jamanetwork.com) Brolucizumab, sold as Beovu by Novartis, also comes with a known safety concern: intraocular inflammation, sometimes with retinal vasculitis or retinal vascular occlusion. A 2022 JAMA Ophthalmology safety study in neovascular age-related macular degeneration found an overall inflammation and-or occlusion rate of about 2.4% in real-world use. (jamanetwork.com) The CONDOR paper’s takeaway was not that laser is obsolete. The authors said brolucizumab can be a suitable alternative to PRP, but the choice should account for visit compliance, cost, and visit frequency as much as the anatomy and vision results. (jamanetwork.com) That leaves the practical question where it started: whether a patient can keep returning for injections and monitoring. Laser is usually delivered in a handful of sessions, while anti-vascular endothelial growth factor therapy can preserve vision and suppress disease only if follow-up holds. (jamanetwork.com) (clinicaltrials.gov)
